Brimonidine Tartrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Brimonidine Tartrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
174
Registered trials
63
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Brimonidine Tartrate can convert its Small molecule drug profile and ADRA2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Brimonidine Tartrate (query alias: brimonidine) |
|---|---|
| Modality / target | Small molecule drug; ADRA2; ADRA2 agonists |
| Highest global status | Approved |
| Originator | Allergan UC |
| Active developers | Galderma International SAS, Allergan, Inc., Tarian Pharma |
The MCP disease footprint includes Eye Redness, Rosacea, Glaucoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-jRCTs031260199 | Phase 4 | 募集中 | 57 | level of faricimab in aqueous humor |
| NCT07431476 | Phase 4 | Completed | 45 | Change in Erythema Index (EI) measured with Mexameter (MX18) |
| ChiCTR2600127004 | Phase 4 | Completed | 20 | Pain score (VAS, Visual Analog Scale) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia
Phase 3; n=469; evaluation: not stated. Reported fields: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision: Odds Ratio (OR) = 7.52, P-Value = <0.0001; Odds Ratio (OR) = 14.55, P-Value = <0.0001; Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision = 64.5 percentage of participants (95% Confidence Interval, 57.076 - 71.920); Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision: Odds Ratio (OR) = 7.52, P-Value = <0.0001; Odds Ratio (OR) = 14.55, P-Value = <0.0001
Assessment of the Effectiveness, Tolerability, and Safety of the Preservative-Free Fixed Combination of Timolol, Dorzolamide, and Brimonidine Compared to Separate Therapies in Patients with Glaucoma, a Randomized Controlled Trial
Phase 3; n=43; evaluation: Positive. Reported fields: IOP(11:00 a.m.) = 9.8 mmHg ; IOP(11:00 a.m.) = 9.3 mmHg ; IOP(11:00 a.m.) = 9.6 mmHg
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
Phase 3; n=380; evaluation: Non-inferior. Reported fields: Ocular Redness(investigator-assessed ,five-minutes to 240-minutes) = The study met its primary objective, confirming that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing ocular redness in adults. Met; Ocular Redness(investigator-assessed ,five-minutes to 240-minutes) = The study met its primary objective, confirming that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing ocular redness in adults. Met
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Brimonidine Tartrate addresses Eye Redness, Rosacea, Glaucoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-17 | Santen Pharmaceutical : China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Eyedrops Products in the Chinese Mainland | Approved | Financial terms not disclosed |
| 2021-12-08 | SPARC licenses development and commercialisation rights of PDP-716 and SDN-037 to Visiox Pharma | Approved | Financial terms not disclosed |
| 2019-11-05 | SPARC inks licensing pact with CMS to commercialise products in China | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Brimonidine tartrate eye drops and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Ocular snedds formulation of brimonidine tartrate for enhanced bioavailability”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
